Hutchin Hill Capital’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Hutchin Hill Capital’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-91,200	Closed	-$935K	–	922
2016 Q3	$935K	Buy	91,200 +2,900	+3%	+$31.6K	0.02%	383
2016 Q2	$1.15M	Buy	88,300 +44,130	+100%	+$578K	0.04%	303
2016 Q1	$486K	Buy	+44,170	New	+$393K	0.01%	521
2015 Q3	–	Sell	-77,300	Closed	-$759K	–	849
2015 Q2	$759K	Buy	77,300 +6,300	+9%	+$57.4K	0.02%	524
2015 Q1	$629K	Buy	+71,000	New	+$566K	0.02%	517
2014 Q4	–	Sell	-29,600	Closed	-$204K	–	768
2014 Q3	$204K	Buy	+29,600	New	+$177K	0.01%	544

Other funds holding SCLN

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Hutchin Hill Capital's SCLN Position: Q4 2016 in Review

Hutchin Hill Capital sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2016, closing a stake of 91,200 shares — an estimated $935K sold.

Hutchin Hill Capital first reported a position in SCLN in Q3 2014 and held it in 6 quarters. The position peaked at $1.15M in Q2 2016. 153 funds tracked by Wall St. Rank hold SCLN as of Q4 2016.

Hutchin Hill Capital reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
Hutchin Hill Capital sold 91,200 Sciclone Pharmaceuticals Inc shares in Q4 2016, an estimated $935K.
Hutchin Hill Capital first reported a position in Sciclone Pharmaceuticals Inc in Q3 2014 and held it in 6 quarters.
Hutchin Hill Capital's Sciclone Pharmaceuticals Inc position peaked at $1.15M in Q2 2016.
153 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2016.

Based on Hutchin Hill Capital's 13F filing for Q4 2016, filed 14 Feb 2017.